eli lilly glp-1 news FDA just approved orforglipron (Foundayo), Lilly's oral receptor agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest Eli Lilly stock pops after

BMI alone is misleading

How CJC-1295 Helps with Depression: Neuroplasticity and Brain Health: Growth hormone and IGF-1 are essential for neurogenesis, the process of forming new neurons in the brain

[DOI] [PMC free article] [PubMed] [Google Scholar] Liz MA, Coelho T, Bellotti V, et al

Diabetes 38: 338-342, 1989

The Super-Responder Cluster (roughly 22 percent of reports): IGF-1 increase of 60 to 120 percent from pre-cycle baseline labs Lean body mass gain of 2 to 4 kg over 12 weeks (confirmed by DEXA in a minority of cases) Subjective sleep quality improvement within 7 to 14 days, particularly reports of more vivid dreams (consistent with REM augmentation) Noticeable skin-thickness and nail-growth changes within 4 to 6 weeks Hunger increase that was manageable rather than uncontrollable The Moderate-Responder Cluster (roughly 55 percent of reports): IGF-1 increase of 20 to 59 percent Lean mass gains of 0.5 to 2 kg over 12 weeks Moderate sleep improvement Hunger increase rated moderate to significant The Low/Non-Responder Cluster (roughly 23 percent of reports): IGF-1 increase below 20 percent or no measurable change No meaningful body-composition shift Predominantly older users (median age 48), higher baseline BMI, poorer sleep, and inconsistent dosing timing These self-report proportions align reasonably well with the trial-level variance seen in the MK-677-024 dataset, where the coefficient of variation for IGF-1 response was 41 percent [1]